Pencarian obat berdasarkan namanya

Fluvoxamine Maleate dan Safinamide

Penentuan interaksi Fluvoxamine Maleate dan Safinamide dan kemungkinan penggunaannya secara bersamaan.

Hasil pengecekan:

Fluvoxamine Maleate <> Safinamide

Aktualitas: 24.06.2022 Pemeriksa: Dr. P.M.Shkutko, in

Dalam database direktori resmi yang digunakan saat membuat layanan, ditemukan interaksi yang tercatat secara statistik oleh hasil penelitian, yang dapat mengarah pada konsekuensi negatif bagi kesehatan pasien, atau meningkatkan efek positif yang saling menguntungkan. Konsultasi dengan dokter diperlukan untuk menjawab masalah penggunaan obat secara bersamaan.

Konsumen:

Menggunakan safinamide bersama-sama dengan fluvoxaMINE dapat meningkatkan risiko yang serius, namun jarang terjadi kondisi yang disebut sindrom serotonin, yang dapat mencakup gejala-gejala seperti kebingungan, halusinasi, kejang, perubahan ekstrim dalam tekanan darah, peningkatan denyut jantung, demam, keringat berlebihan, menggigil atau gemetar, penglihatan kabur, kejang otot atau kekakuan, tremor, inkoordinasi, kram perut, mual, muntah, dan diare. Dokter mungkin dapat meresepkan alternatif yang tidak berinteraksi, atau anda mungkin perlu pemantauan lebih sering untuk aman menggunakan kedua obat-obatan. Bicarakan dengan dokter anda jika anda memiliki pertanyaan atau masalah. Hal ini penting untuk memberitahu dokter anda tentang semua obat lain yang anda gunakan, termasuk vitamin dan rempah-rempah. Jangan berhenti menggunakan obat apapun tanpa terlebih dahulu berbicara dengan dokter anda.

Profesional:

MONITOR: Dengan menghambat metabolisme serotonin, monoamine oxidase inhibitors (MAOIs), termasuk selektif MAO-B inhibitor safinamide, dapat mempotensiasi aktivitas farmakologi dari agen serotonergik seperti serotonin reuptake inhibitor (Ssri). Hasil dapat menjadi peningkatan risiko sindrom serotonin, yang jarang namun serius dan berpotensi fatal diduga hasil dari hiperstimulasi dari batang otak 5-HT1A dan 2A reseptor. Gejala sindrom serotonin dapat mencakup perubahan status mental seperti mudah marah, gangguan kesadaran, kebingungan, halusinasi, dan koma; disfungsi otonom seperti takikardia, hipertermia, diaphoresis, menggigil, tekanan darah labil, dan midriasis; kelainan neuromuskuler seperti hyperreflexia, myoclonus, tremor, kekakuan, dan ataksia; dan gejala pada saluran pencernaan seperti kram perut, mual, muntah, dan diare.

MANAJEMEN: hati-Hati disarankan jika safinamide digunakan bersamaan dengan Ssri dan SSRI harus diberikan pada dosis efektif terendah. Pemantauan klinis dan laboratorium yang harus dipertimbangkan ketika obat ini digunakan secara bersamaan.

Sumber

Corkeron MA "Serotonin syndrome - a potentially fatal complication of antidepressant therapy." Med J Aust 163 (1995): 481-2
Weiner LA, Smythe M, Cisek J "Serotonin syndrome secondary to phenelzine-venlafaxine interaction." Pharmacotherapy 18 (1998): 399-403
Diamond S "The use of sumatriptan in patients on monoamine oxidase inhibitors." Neurology 45 (1995): 1039-40
Cerner Multum, Inc. "Australian Product Information." O 0
Gillman PK "Monoamine oxidase inhibitors, opioid analgesics and serotonin toxicity." Br J Anaesth (2005):
Mills KC "Serotonin syndrome: A clinical update." Crit Care Clin 13 (1997): 763
Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0
"Product Information. D.H.E. 45 (dihydroergotamine)." Sandoz Pharmaceuticals Corporation, East Hanover, NJ.
Martin TG "Serotonin syndrome." Ann Emerg Med 28 (1996): 520-6
Brubacher JR, Hoffman RS, Lurin MJ "Serotonin syndrome from venlafaxine-tranylcypromine interaction." Vet Hum Toxicol 38 (1996): 358-61
Graham PM, Ilett KF "Danger of MAOI therapy after fluoxetine withdrawal." Lancet 2 (1988): 1255-6
Darcy PF, Griffin JP "Interactions with drugs used in the treatment of depressive illness." Adverse Drug React Toxicol Rev 14 (1995): 211-31
Jimenez-Genchi A "Immediate switching from moclobemide to duloxetine may induce serotonin syndrome." J Clin Psychiatry 67 (2006): 1821-1822
Klysner R, Larsen JK, Sorensen P, Hyllested M, Pedersen BD "Toxic interaction of venlafaxine and isocarboxazide." Lancet 346 (1995): 1298-9
"Product Information. Xadago (safinamide)." US WorldMeds LLC, Louisville , KY.
White K, Simpson G "Combined MAOI-tricyclic antidepressant treatment: a reevaluation." J Clin Psychopharmacol 1 (1981): 264-82
Sternbach H "The serotonin syndrome." Am J Psychiatry 148 (1991): 705-13
Nierenberg DW, Semprebon M "The central nervous system serotonin syndrome." Clin Pharmacol Ther 53 (1993): 84-8
Spiker DG, Pugh DD "Combining tricyclic and monoamine oxidase inhibitor antidepressants." Arch Gen Psychiatry 33 (1976): 828-30
Sternbach H "Danger of MAOI therapy after fluoxetine withdrawal." Lancet 2 (1988): 850-1
Jacob JE, Wagner ML, Sage JI "Safety of selegiline with cold medications." Ann Pharmacother 37 (2003): 438-41
"Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories, Philadelphia, PA.
Sovner R, Wolfe J "Interaction between dextromethorphan and monoamine oxidase inhibitor therapy with isocarboxazid ." N Engl J Med 319 (1988): 1671
Beasley CM Jr, Masica DN, Heiligenstein JH, Wheadon DE, Zerbe RL "Possible monoamine oxidase inhibitor-serotonin uptake inhibitor interaction: fluoxetine clinical data and preclinical findings." J Clin Psychopharmacol 13 (1993): 312-20
Feighner JP, Boyer WF, Tyler DL, Neborsky RJ "Adverse consequences of fluoxetine-MAOI combination therapy." J Clin Psychiatry 51 (1990): 222-5
Heisler MA, Guidry JR, Arnecke B "Serotonin syndrome induced by administration of venlafaxine and phenelzine." Ann Pharmacother 30 (1996): 84
Diamond S, Pepper BJ, Diamond ML, Freitag FG, Urban GJ, Erdemoglu AK "Serotonin syndrome induced by transitioning from phenelzine to venlafaxine: four patient reports." Neurology 51 (1998): 274-6
"Product Information. Viibryd (vilazodone)." Trovis Pharmaceuticals LLC, New Haven, CT.
"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories, Philadelphia, PA.
Staufenberg EF, Tantam D "Malignant hyperpyrexia syndrome in combined treatment." Br J Psychiatry 154 (1989): 577-8
Phillips SD, Ringo P "Phenelzine and venlafaxine interaction." Am J Psychiatry 152 (1995): 1400-1
Bem JL, Peck R "Dextromethorphan. An overview of safety issues." Drug Saf 7 (1992): 190-9
Graber MA, Hoehns TB, Perry PJ "Sertraline-phenelzine drug interaction: a serotonin syndrome reaction." Ann Pharmacother 28 (1994): 732-5
Pope HG Jr, Jonas JM, Hudson JI, Kafka MP "Toxic reactions to the combination of monoamine oxidase inhibitors and tryptophan." Am J Psychiatry 142 (1985): 491-2
Miller LG "Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions." Arch Intern Med 158 (1998): 2200-11
Fischer P "Serotonin syndrome in the elderly after antidepressive monotherapy." J Clin Psychopharmacol 15 (1995): 440-2
Gardner DM, Lynd LD "Sumatriptan contraindications and the serotonin syndrome." Ann Pharmacother 32 (1998): 33-8
Mathew NT, Tietjen GE, Lucker C "Serotonin syndrome complicating migraine pharmacotherapy." Cephalalgia 16 (1996): 323-7
Bhatara VS, Bandettini FC "Possible interaction between sertraline and tranylcypromine." Clin Pharm 12 (1993): 222-5
Pettinger WA, Soyangco FG, Oates JA "Inhibition of monoamine oxidase in man by furazolidone." Clin Pharmacol Ther 9 (1968): 442-7
"Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals, St. Louis, MO.
Brannan SK, Talley BJ, Bowden CL "Sertraline and isocarboxazid cause a serotonin syndrome." J Clin Psychopharmacol 14 (1994): 144-5
"Product Information. Savella (milnacipran)." Forest Pharmaceuticals, St. Louis, MO.
Thomas JM, Rubin EH "Case report of a toxic reaction from a combination of tryptophan and phenelzine." Am J Psychiatry 141 (1984): 281-3
Bodner RA, Lynch T, Lewis L, Kahn D "Serotonin syndrome." Neurology 45 (1995): 219-23
Levy AB, Bucher P, Votolato N "Myoclonus, hyperreflexia and diaphoresis in patients on phenelzine- tryptophan combination treatment." Can J Psychiatry 30 (1985): 434-6
"Product Information. Manerix (moclobemide)." Hoffmann-La Roche Limited, Mississauga, IA.
Suchowersky O, deVries JD "Interaction of fluoxetine and selegiline." Can J Psychiatry 35 (1990): 571-2
Alvine G, Black DW, Tsuang D "Case of delirium secondary to phenelzine/L-tryptophan combination." J Clin Psychiatry 51 (1990): 311
Graham PM, Potter JM, Paterson J "Combination monoamine oxidase inhibitor/tricyclic antidepressants interaction." Lancet 2 (1982): 440
Rivers N, Horner B "Possible lethal reaction between nardil and dextromethorphan." Can Med Assoc J 103 (1970): 85
De Vita VT, Hahn MA, Oliverio VT "Monoamine oxidase inhibition by a new carcinostatic agent, n-isopropyl-a-(2-methylhydrazino)-p-toluamide (MIH). (30590)." Proc Soc Exp Biol Med 120 (1965): 561-5
Schulz R, Antonin KH, Hoffmann E, et al "Tyramine kinetics and pressor sensitivity during monoamine oxidase inhibition by selegiline." Clin Pharmacol Ther 46 (1989): 528-36
White K, Pistole T, Boyd JL "Combined monoamine oxidase inhibitor-tricyclic antidepressant treatment: a pilot study." Am J Psychiatry 137 (1980): 1422-5
"Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company, Indianapolis, IN.
Chan BSH, Graudins A, Whyte IM, Dawson AH, Braitberg G, Duggin GG "Serotonin syndrome resulting from drug interactions." Med J Aust 169 (1998): 523-5
Cetaruk EW, Aaron CK "Hazards of nonprescription medications." Emerg Med Clin North Am 12 (1994): 483-510